Last reviewed · How we verify

IPV at 6 weeks of age

Centers for Disease Control and Prevention · FDA-approved active Biologic

IPV at 6 weeks of age is a Inactivated viral vaccine Biologic drug developed by Centers for Disease Control and Prevention. It is currently FDA-approved for Prevention of poliomyelitis in infants and children, Routine immunization at 6 weeks of age as part of childhood vaccination schedule.

IPV (Inactivated Poliovirus Vaccine) stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3 by introducing inactivated viral particles.

IPV (Inactivated Poliovirus Vaccine) stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3 by introducing inactivated viral particles. Used for Prevention of poliomyelitis in infants and children, Routine immunization at 6 weeks of age as part of childhood vaccination schedule.

At a glance

Generic nameIPV at 6 weeks of age
SponsorCenters for Disease Control and Prevention
Drug classInactivated viral vaccine
TargetPoliovirus types 1, 2, and 3
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

IPV contains chemically inactivated (killed) poliovirus strains that cannot cause disease but retain their antigenic properties. When administered, these inactivated viruses trigger both humoral (antibody) and cellular immune responses, leading to the production of neutralizing antibodies against all three poliovirus serotypes. This provides protection against wild-type poliovirus infection and prevents poliomyelitis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about IPV at 6 weeks of age

What is IPV at 6 weeks of age?

IPV at 6 weeks of age is a Inactivated viral vaccine drug developed by Centers for Disease Control and Prevention, indicated for Prevention of poliomyelitis in infants and children, Routine immunization at 6 weeks of age as part of childhood vaccination schedule.

How does IPV at 6 weeks of age work?

IPV (Inactivated Poliovirus Vaccine) stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3 by introducing inactivated viral particles.

What is IPV at 6 weeks of age used for?

IPV at 6 weeks of age is indicated for Prevention of poliomyelitis in infants and children, Routine immunization at 6 weeks of age as part of childhood vaccination schedule.

Who makes IPV at 6 weeks of age?

IPV at 6 weeks of age is developed and marketed by Centers for Disease Control and Prevention (see full Centers for Disease Control and Prevention pipeline at /company/centers-for-disease-control-and-prevention).

What drug class is IPV at 6 weeks of age in?

IPV at 6 weeks of age belongs to the Inactivated viral vaccine class. See all Inactivated viral vaccine drugs at /class/inactivated-viral-vaccine.

What development phase is IPV at 6 weeks of age in?

IPV at 6 weeks of age is FDA-approved (marketed).

What are the side effects of IPV at 6 weeks of age?

Common side effects of IPV at 6 weeks of age include Local injection site reactions (pain, redness, swelling), Fever, Irritability or fussiness, Mild rash.

What does IPV at 6 weeks of age target?

IPV at 6 weeks of age targets Poliovirus types 1, 2, and 3 and is a Inactivated viral vaccine.

Related